What pharmacologic agents can be used to manage agitation?

Pharmacologic Management of Agitation

For acute agitation in adult patients, use intramuscular antipsychotics (haloperidol, droperidol, ziprasidone, or olanzapine) or benzodiazepines (midazolam or lorazepam) as first-line agents, with combination therapy often providing superior efficacy and faster onset than monotherapy. 1, 2

Emergency/Acute Settings

First-Line Agents for Rapid Tranquilization

Fastest onset options when immediate sedation is required:

• Droperidol 5-10 mg IM provides the fastest sedation as monotherapy, comparable efficacy to olanzapine but with more rapid onset 2
• Midazolam 5-10 mg IM has the fastest onset among benzodiazepines when used alone 2
• Combination therapy (antipsychotic + benzodiazepine) demonstrates superior improvement rates and lower extrapyramidal side effects compared to either agent alone 3
  • Midazolam combined with an antipsychotic produces faster sedation than lorazepam combinations 2
  • Haloperidol with promethazine effectively reduces aggression with lower adverse effects 1

Atypical Antipsychotics (Preferred When Available)

Atypical antipsychotics should be considered first-line due to better tolerability profiles 3:

• Ziprasidone IM: Significant calming effects within 30 minutes, faster onset and better tolerated than haloperidol, but avoid in patients with QTc prolongation risk 1, 4
• Olanzapine IM: Faster onset, greater efficacy, and fewer adverse effects than haloperidol or lorazepam; shows distinct calming versus nonspecific sedative effects 4
  • Critical caveat: Avoid simultaneous use with other CNS depressants due to reports of fatalities; follow strict prescribing guidelines 4
• Aripiprazole: Effective with less sedation than olanzapine 1
• Loxapine 10 mg inhaled: Superior to 5 mg dose, provides rapid relief in acute psychosis 1

Traditional Agents

• Haloperidol: Widely used, effective across diagnostic categories, can be used in medically compromised patients, but causes significant extrapyramidal symptoms and rarely associated with cardiac arrhythmia/sudden death 4
  • Requires fewer additional doses but less effective at 60 minutes compared to some alternatives 1
• Lorazepam: Effective with fewer side effects than antipsychotics, enhanced efficacy when combined with antipsychotics, but causes ataxia, sedation, and has additive CNS depressant effects 1, 4

Second-Line Agent

• Ketamine: Reserved when antipsychotics and benzodiazepines fail 2
  • Standard dose (5 mg/kg IM) more frequently associated with airway compromise requiring intubation 2
  • Low-dose ketamine (2 mg/kg IM) reduces airway compromise risk while providing adequate sedation 2

ICU Setting (Non-Emergency Agitation)

Address underlying causes first before administering sedatives 5:

• Identify and treat pain, delirium, hypoxemia, hypoglycemia, hypotension, or withdrawal states 5
• Implement nonpharmacological interventions: maintain patient comfort, provide adequate analgesia, frequent reorientation, optimize environment for normal sleep patterns 5
• Titrate sedatives to maintain light sedation (patient arousable and able to purposefully follow simple commands) 5

Dementia-Related Agitation

Antipsychotics should only be used when symptoms are severe, dangerous, and/or cause significant distress 5:

• Review nonpharmacological interventions prior to antipsychotic use 5
• Initiate at low dose, titrate to minimum effective dose 5
• Discontinue after 4-week trial if no clinically significant response 5
• Discuss risks/benefits with patient (if feasible) and surrogate decision maker before initiating 5
• Consider tapering in responders after discussing with patient/family, reviewing initial goals, observed benefits, side effects, and risks of continued exposure 5

Key Clinical Pearls

• Always offer oral treatment first to build alliance and suggest internal locus of control 3
• Atypical antipsychotics allow ease of transition to same-agent oral therapy once acute agitation diminishes 4
• Combination therapy generally superior to monotherapy for both efficacy and safety profile 3
• Monitor for QTc prolongation with ziprasidone and avoid in at-risk patients 4
• Avoid combining olanzapine IM with other CNS depressants 4